Welcome to our dedicated page for Genelux SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cancer-therapy breakthroughs come with equally complex disclosures. Genelux Corp’s oncolytic virus research means its SEC filings can span hundreds of pages filled with trial data, cash-burn details, and patent milestones—information that’s vital yet hard to digest.
Stock Titan turns that problem on its head. Our AI reads every Genelux quarterly earnings report 10-Q filing, flags R&D spend trends, and translates 300-page 10-Ks into plain language you can scan in minutes. Need to track Genelux insider trading Form 4 transactions? We stream Genelux Form 4 insider transactions real-time, highlighting buys or sells before they hit your inbox. When a sudden clinical result lands, our dashboard pairs the raw 8-K with “Genelux 8-K material events explained” notes so you see impact, not jargon.
Every filing type is covered:
- 10-K: Genelux annual report 10-K simplified for cash runway, pipeline risk, and CHOICE™ platform IP.
- 10-Q: Quarter-over-quarter trial spending with Genelux earnings report filing analysis.
- Form 4: Alerts on Genelux executive stock transactions Form 4.
- DEF 14A: Genelux proxy statement executive compensation breakdown.
The result? Genelux SEC filings explained simply. Use our AI summaries to compare trial milestones, spot dilution signals, or prepare questions for the next earnings call. Stop scrolling through PDFs—start understanding Genelux SEC documents with AI and make informed decisions faster.
Genelux Corporation director Mary Mirabelli received equity awards on 08/27/2025 consisting of 22,283 restricted stock units and a stock option for 28,576 shares. The RSUs convert to one share each upon vesting and will vest on the earlier of the one-year anniversary of grant or the company’s next annual meeting. The option has a $3.64 exercise price and expires 08/26/2035; the option shares vest on the same schedule as the RSUs.
After these grants Mirabelli beneficially owns 73,284 shares of common stock and 28,576 option shares. The awards were granted under the Issuer’s 2022 Equity Incentive Plan and appear intended as retention/compensation for a director role.
Genelux Corporation director Tyree James L reported insider grants and ownership changes on 08/27/2025. The filing discloses the grant of 22,283 restricted stock units (RSUs) under the Issuer's 2022 Equity Incentive Plan; each RSU represents the contingent right to receive one share of common stock upon vesting. After the RSU grant, the reporting person beneficially owned 68,074 shares.
The filing also shows an option grant of 28,576 stock options with a $3.64 exercise price, exercisable and expiring on 08/26/2035. The RSUs and options vest upon the earlier of the one-year anniversary of grant and the Issuer's next annual meeting of stockholders. The form was signed by an attorney-in-fact on 08/29/2025.
Joseph Cappello, Chief Technical Officer of Genelux Corporation (GNLX), reported insider awards and holdings following transactions dated 08/27/2025. He was granted 107,500 restricted stock units (RSUs) that convert to one share each upon vesting and received a stock option covering 142,500 shares with an exercise price of $3.64 and an expiration date of 08/26/2035. After these transactions he beneficially owns 159,766 shares of common stock and 142,500 option shares. The RSUs vest 25% after one year and then in 12 equal quarterly installments; the option vests 25% after one year and then in 36 equal monthly installments.
FAQ
What is the current stock price of Genelux (GNLX)?
What is the market cap of Genelux (GNLX)?
